UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

IMPROVING PRECISION BY APPLYING DISEASE PROGRESSION EQUATIONS FROM MULTIPLE SOURCES IN THE ALZHEIMER’S DISEASE ARCHIMEDES CONDITION EVENT (ACE) SIMULATOR

Value in health, 2016-05, Vol.19 (3), p.A85-A85

2016

Volltextzugriff (PDF)

MODELING CARDIOVASCULAR OUTCOMES OF TREATMENT WITH EMPAGLIFLOZIN IN TYPE 2 DIABETES BASED ON HARD OUTCOMES DATA

Value in health, 2016-05, Vol.19 (3), p.A203-A203

2016

Volltextzugriff (PDF)

Treatment Effects On The Cost Burden Of Hospitalizations In Patients With Chronic Systolic Heart Failure

Value in health, 2015-05, Vol.18 (3), p.A139-A139

2015

Volltextzugriff (PDF)

Use of hormonal therapy in senior breast cancer patients treated with or without radiotherapy

Current oncology (Toronto), 2014-02, Vol.21 (1), p.e105-e115

2014

Volltextzugriff (PDF)

Factors influencing the quality of local management of ductal carcinoma in situ: a cohort study

Current oncology (Toronto), 2013-06, Vol.20 (3), p.e212-222

2013

Volltextzugriff (PDF)

PRM80 - IMPROVING PRECISION BY APPLYING DISEASE PROGRESSION EQUATIONS FROM MULTIPLE SOURCES IN THE ALZHEIMER’S DISEASE ARCHIMEDES CONDITION EVENT (ACE) SIMULATOR

Value in health, 2016-05, Vol.19 (3), p.A85-A85

2016

Volltextzugriff (PDF)

PCV54 - Treatment Effects On The Cost Burden Of Hospitalizations In Patients With Chronic Systolic Heart Failure

Value in health, 2015-05, Vol.18 (3), p.A139-A139

2015

Volltextzugriff (PDF)

PDB37 - MODELING CARDIOVASCULAR OUTCOMES OF TREATMENT WITH EMPAGLIFLOZIN IN TYPE 2 DIABETES BASED ON HARD OUTCOMES DATA

Value in health, 2016-05, Vol.19 (3), p.A203-A203

2016

Volltextzugriff (PDF)

African Program for Onchocerciasis Control 1995-2010: Impact of Annual Ivermectin Mass Treatment on Off-Target Infectious Diseases

PLoS neglected tropical diseases, 2015-09, Vol.9 (9), p.e0004051-e0004051

2015

Volltextzugriff (PDF)

Anchored matching-adjusted indirect comparison (MAIC) of regorafenib (REG) versus cabozantinib (CAB) in advanced hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e16188-e16188

2021

Volltextzugriff (PDF)

Medication reconciliation at admission and discharge: a time and motion study

BMC health services research, 2013-11, Vol.13 (1), p.485-485, Article 485

2013

Volltextzugriff (PDF)

Regorafenib vs. cabozantinib as second-line treatment for advanced hepatocellular carcinoma: an anchored matching-adjusted indirect comparison of efficacy and safety

Liver cancer (Basel ), 2023-06

2023

Volltextzugriff (PDF)

Capturing Latency in Cognitive Symptoms for People with Significant Memory Concern (P5.190)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Cost‐Effectiveness of Ivabradine for Heart Failure in the United States

Journal of the American Heart Association, 2016-05, Vol.5 (5), p.n/a

2016

Volltextzugriff (PDF)

Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer

Current medical research and opinion, 2019-04, Vol.35 (4), p.569-576

2019

Volltextzugriff (PDF)

Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety

Liver cancer (Basel ), 2023-06, Vol.12 (2), p.145-155

2023

Volltextzugriff (PDF)

Prognostic factors in crizotinib (CRZ)-resistant anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC) patients (Pts)

Annals of oncology, 2017-04, Vol.28, p.ii38-ii39

2017

Volltextzugriff (PDF)

Important Statistical Considerations For Developing Equations For Disease Simulators

Value in health, 2015-05, Vol.18 (3), p.A35-A35

2015

Volltextzugriff (PDF)

Cost-Effectiveness Analysis of Daratumumab, Lenalidomide, and Dexamethasone (DRD) and Daratumumab, Bortezomib, And Dexamethasone (DVD) Versus Standard of Care in Relapsed or Refractory Multiple Myeloma (RRMM)

Value in health, 2018-05, Vol.21, p.S254

2018

Volltextzugriff (PDF)

PSY55 - Cost-Effectiveness Analysis of Daratumumab, Lenalidomide, and Dexamethasone (DRD) and Daratumumab, Bortezomib, And Dexamethasone (DVD) Versus Standard of Care in Relapsed or Refractory Multiple Myeloma (RRMM)

Value in health, 2018-05, Vol.21, p.S254-S254

2018

Volltextzugriff (PDF)

Matching-adjusted indirect comparison (MAIC) of relative efficacy for brigatinib vs. ceritinib and alectinib in crizotinib-resistant anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e20675-e20675

2017

Volltextzugriff (PDF)

Abstract 17655: Cost-effectiveness of Ivabradine as a Treatment for Systolic Chronic Heart Failure in the United States

Circulation (New York, N.Y.), 2015-11, Vol.132 (Suppl_3 Suppl 3), p.A17655-A17655

2015

Volltextzugriff (PDF)

Matching-Adjusted Indirect Comparison of Relative Efficacies Is Feasible and Useful in the Multiple Myeloma Therapy Landscape: A Comparison of Pomalidomide Plus Low-Dose Dexamethasone Versus Daratumumab

Blood, 2016-12, Vol.128 (22), p.5946-5946

2016

Volltextzugriff (PDF)

Improved targeting of cancer care for older patients: A systematic review of the utility of comprehensive geriatric assessment

Journal of geriatric oncology, 2013-07, Vol.4 (3), p.271-281

2013

Volltextzugriff (PDF)

O3‐14‐06: Assessment of the incremental prognostic utility of clinical diagnosis in equations for disease progression in Alzheimer's disease

Alzheimer's & dementia, 2015-07, Vol.11 (7S_Part_5), p.P256-P257

2015

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(41)

Sprache

Englisch
(41)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(12)
Science & Technology
(12)
Humans
(9)
Internal Medicine
(6)
Oncology
(6)
Aged
(5)
Female
(5)
Middle Aged
(5)
Male
(4)
Cancer
(3)
Health Risk Assessment
(3)
Literature Reviews
(3)
Patients
(3)
Radiotherapy
(3)
Adult
(2)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(2)
Benzazepines - Economics
(2)
Benzazepines - Therapeutic Use
(2)
Breast Cancer
(2)
Cardiovascular Agents - Economics
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

IMPROVING PRECISION BY APPLYING DISEASE PROGRESSION EQUATIONS FROM MULTIPLE SOURCES IN THE ALZHEIMER’S DISEASE ARCHIMEDES CONDITION EVENT (ACE) SIMULATOR

MODELING CARDIOVASCULAR OUTCOMES OF TREATMENT WITH EMPAGLIFLOZIN IN TYPE 2 DIABETES BASED ON HARD OUTCOMES DATA

Treatment Effects On The Cost Burden Of Hospitalizations In Patients With Chronic Systolic Heart Failure

Use of hormonal therapy in senior breast cancer patients treated with or without radiotherapy

Factors influencing the quality of local management of ductal carcinoma in situ: a cohort study

PRM80 - IMPROVING PRECISION BY APPLYING DISEASE PROGRESSION EQUATIONS FROM MULTIPLE SOURCES IN THE ALZHEIMER’S DISEASE ARCHIMEDES CONDITION EVENT (ACE) SIMULATOR

PCV54 - Treatment Effects On The Cost Burden Of Hospitalizations In Patients With Chronic Systolic Heart Failure

PDB37 - MODELING CARDIOVASCULAR OUTCOMES OF TREATMENT WITH EMPAGLIFLOZIN IN TYPE 2 DIABETES BASED ON HARD OUTCOMES DATA

African Program for Onchocerciasis Control 1995-2010: Impact of Annual Ivermectin Mass Treatment on Off-Target Infectious Diseases

Anchored matching-adjusted indirect comparison (MAIC) of regorafenib (REG) versus cabozantinib (CAB) in advanced hepatocellular carcinoma (HCC)

Medication reconciliation at admission and discharge: a time and motion study

Regorafenib vs. cabozantinib as second-line treatment for advanced hepatocellular carcinoma: an anchored matching-adjusted indirect comparison of efficacy and safety

Capturing Latency in Cognitive Symptoms for People with Significant Memory Concern (P5.190)

Cost‐Effectiveness of Ivabradine for Heart Failure in the United States

Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer

Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety

Prognostic factors in crizotinib (CRZ)-resistant anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC) patients (Pts)

Important Statistical Considerations For Developing Equations For Disease Simulators

Cost-Effectiveness Analysis of Daratumumab, Lenalidomide, and Dexamethasone (DRD) and Daratumumab, Bortezomib, And Dexamethasone (DVD) Versus Standard of Care in Relapsed or Refractory Multiple Myeloma (RRMM)

PSY55 - Cost-Effectiveness Analysis of Daratumumab, Lenalidomide, and Dexamethasone (DRD) and Daratumumab, Bortezomib, And Dexamethasone (DVD) Versus Standard of Care in Relapsed or Refractory Multiple Myeloma (RRMM)

Matching-adjusted indirect comparison (MAIC) of relative efficacy for brigatinib vs. ceritinib and alectinib in crizotinib-resistant anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC)

Abstract 17655: Cost-effectiveness of Ivabradine as a Treatment for Systolic Chronic Heart Failure in the United States

Matching-Adjusted Indirect Comparison of Relative Efficacies Is Feasible and Useful in the Multiple Myeloma Therapy Landscape: A Comparison of Pomalidomide Plus Low-Dose Dexamethasone Versus Daratumumab

Improved targeting of cancer care for older patients: A systematic review of the utility of comprehensive geriatric assessment

O3‐14‐06: Assessment of the incremental prognostic utility of clinical diagnosis in equations for disease progression in Alzheimer's disease

Suchergebnisse filtern